Orchestra BioMed Holdings (OBIO) just posted a sharp step up in activity for FY 2025, with fourth quarter revenue at US$30.9 million and basic EPS of US$0.10, compared with a full year where trailing twelve month revenue sat at US$33.5 million and EPS on that basis was a loss of US$1.11. The company has seen revenue move from quarterly levels below US$1 million through most of the year to the current US$30.9 million print, while quarterly basic EPS shifted from losses between US$0.49 and US$0.50 in the first three quarters of 2025 to a positive US$0.10 in Q4. This sets up a story where higher sales are starting to bite into heavy losses. For investors, the key question now is whether this revenue ramp can eventually support more durable margins rather than a one off shift.

See our full analysis for Orchestra BioMed Holdings.

With the latest numbers on the table, the next step is to see how this mix of rising revenue and still negative EPS lines up against the main narratives around growth potential and profitability risk.

Q4 swing to US$6m profit versus year long losses

• Q4 FY 2025 net income was US$5.99 million, while the latest trailing 12 month figure still shows a loss of US$52.96 million, so the single profitable quarter sits against a full year that is firmly in loss making territory.
• What stands out for the bullish view is how quickly the math changed, with Q4 revenue at US$30.92 million and net income positive. This compares with Q1 to Q3 2025 revenue between US$0.84 million and US$0.87 million and quarterly losses of US$18.76 million to US$20.83 million, which strongly supports the bullish argument that higher sales can absorb a large fixed cost base. However, the trailing 12 month loss shows that this is not yet a steady pattern.

High forecast growth but no near term profitability

• The analysis data describes revenue as forecast to grow at about 39.3% per year, while also stating the company is expected to remain unprofitable for at least the next three years and that losses have grown at about 24.1% per year over the past five years. This means growth and continued losses sit side by side in the outlook.
• Bears focus on that combination, arguing that an unprofitable company with losses deepening over time and not forecast to reach profitability soon faces real earnings risk. The data here aligns with that view because trailing 12 month net income remains a US$52.96 million loss even after the profitable Q4, and EPS on that basis is a loss of US$1.11, which challenges any idea that one quarter has already fixed the earnings profile.

High growth without a clear path to near term profits is exactly what skeptics point to in small medtech names, so this mix of a profitable quarter and ongoing losses keeps the bearish case in play. 🐻 Orchestra BioMed Holdings Bear Case

Rich P/S multiple against industry and DCF gap

• The shares are cited as trading at US$4.20 with a P/S of 7.1x, compared with the US Medical Equipment industry average of 2.8x and a peer average of 8.6x, while the supplied DCF fair value is US$34.96. The stock is therefore described as priced at a premium to the broader industry on sales but at a large discount to that DCF fair value.
• Supporters emphasize that gap between the current US$4.20 share price and the US$34.96 DCF fair value, arguing there is sizable upside implied by the model. Yet the same dataset highlights substantial shareholder dilution over the last year and ongoing unprofitability with a US$52.96 million trailing 12 month loss, so the bullish case of potential value has to be weighed directly against the cost of funding those losses.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Orchestra BioMed Holdings's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Seeing both the hopeful and cautious threads in this story, it is worth moving quickly to check the full balance of risks and rewards for yourself, starting with 2 key rewards and 2 important warning signs.

See What Else Is Out There

OBIO still carries a US$52.96 million trailing loss, no clear near term path to profitability and a relatively rich P/S multiple versus its industry.

If you want ideas that lean more toward quality and valuation support right now, take a look at our 48 high quality undervalued stocks that could better fit your risk tolerance.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.